Evommune, Inc. (EVMN)
NYSE: EVMN · Pharmaceutical Preparations · Palo Alto, CA · filing with the SEC since 2025
Who owns Evommune, Inc.
As filed with the SECHolders of 5% or more
5
LSP 7 Cooperatieve U.A. holds 14.7% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Feb 19, 2026 says.
Directors and officers
21
report now, of 21 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
LSP 7 Cooperatieve U.A.
SCHEDULE 13D/A · filed Feb 19, 2026 · Common Stock, $0.0001 par value per share · 15.7% in Nov 14, 2025
Nan Fung Group Holdings Limited
SCHEDULE 13G · filed Feb 13, 2026 · Common Stock, par value $0.0001 per share
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · 11% in Nov 17, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · COMMON STOCK
Point72 Asset Management, L.P.
SCHEDULE 13G · filed Jul 16, 2026 · Common Stock, par value $0.0001 per share
Andera Partners
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6% in Nov 17, 2025
What EVMN reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 5, 2026.
Insider tradesForm 4
9sales
7purchases
9sales on a scheduled plan
6people selling
$2.3Msold, in dollars
$70.2Mbought, in dollars
Open-market trades on Form 4 from Oct 15, 2025 to Oct 15, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 15, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 21 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Pena Luis C. | President & CEO | 2 | $600,000 | 2 | 0 | $0 |
| Drew Janice Suzann | Chief of Dev. Operations | 1 | $500,000 | 1 | 0 | $0 |
| Carver Kyle | Chief Financial Officer | 1 | $400,000 | 1 | 1 | $0 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | 2 | $400,000 | 2 | 0 | $0 |
| Moss Gregory S. | Chief Business & Legal Officer | 1 | $300,000 | 1 | 0 | $0 |
| Cohen David E | director | 2 | $100,000 | 2 | 0 | $0 |
| Ra Capital Management, L.P. | director | 0 | $0 | 0 | 2 | $20.0M |
| Kirsch Arthur S | director | 0 | $0 | 0 | 1 | $100,000 |
| Lsp 7 Cooperative Ua | director | 0 | $0 | 0 | 1 | $25.0M |
| Verduyn-Van Weegen Felice Isabel | director | 0 | $0 | 0 | 1 | $25.0M |
| Hopfner Robert Lorne | director | 0 | $0 | 0 | 1 | $0 |